REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 3 filers reported holding REATA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $21,026,497 | +87.7% | 206,223 | +67.3% | 0.00% | +100.0% |
| Q1 2023 | $11,204,000 | +176035.8% | 123,243 | -26.4% | 0.00% | 0.0% |
| Q4 2022 | $6,361 | -99.8% | 167,416 | +25.8% | 0.00% | – |
| Q3 2022 | $3,345,000 | +148.3% | 133,060 | +200.3% | 0.00% | – |
| Q2 2022 | $1,347,000 | +45.9% | 44,310 | +57.3% | 0.00% | – |
| Q1 2022 | $923,000 | +47.2% | 28,162 | +18.5% | 0.00% | – |
| Q4 2021 | $627,000 | -76.1% | 23,764 | -8.7% | 0.00% | – |
| Q3 2021 | $2,620,000 | -25.4% | 26,037 | +5.0% | 0.00% | – |
| Q2 2021 | $3,510,000 | -5.1% | 24,795 | -33.1% | 0.00% | – |
| Q1 2021 | $3,697,000 | -26.9% | 37,080 | -9.4% | 0.00% | -100.0% |
| Q4 2020 | $5,060,000 | +45.9% | 40,934 | +11.9% | 0.00% | 0.0% |
| Q3 2020 | $3,468,000 | -46.7% | 36,594 | -12.3% | 0.00% | 0.0% |
| Q2 2020 | $6,512,000 | +7.0% | 41,735 | -1.0% | 0.00% | 0.0% |
| Q1 2020 | $6,084,000 | -46.2% | 42,148 | -23.8% | 0.00% | -50.0% |
| Q4 2019 | $11,314,000 | +143.2% | 55,340 | -4.5% | 0.00% | +100.0% |
| Q3 2019 | $4,652,000 | -7.3% | 57,948 | +5.7% | 0.00% | 0.0% |
| Q2 2019 | $5,020,000 | +1.9% | 54,830 | -4.8% | 0.00% | 0.0% |
| Q1 2019 | $4,924,000 | +2.9% | 57,624 | -32.4% | 0.00% | 0.0% |
| Q4 2018 | $4,783,000 | -52.7% | 85,258 | -31.1% | 0.00% | -50.0% |
| Q3 2018 | $10,111,000 | +92.8% | 123,672 | -17.5% | 0.00% | +100.0% |
| Q2 2018 | $5,244,000 | +51.5% | 149,988 | -11.1% | 0.00% | 0.0% |
| Q1 2018 | $3,462,000 | -45.5% | 168,762 | -24.7% | 0.00% | 0.0% |
| Q4 2017 | $6,347,000 | -10.7% | 224,154 | -2.0% | 0.00% | -50.0% |
| Q3 2017 | $7,110,000 | -3.4% | 228,612 | -1.7% | 0.00% | 0.0% |
| Q2 2017 | $7,359,000 | +148.8% | 232,562 | +78.1% | 0.00% | +100.0% |
| Q1 2017 | $2,958,000 | -6.6% | 130,593 | -10.0% | 0.00% | 0.0% |
| Q4 2016 | $3,167,000 | -14.6% | 145,093 | +3.1% | 0.00% | 0.0% |
| Q3 2016 | $3,708,000 | -22.7% | 140,678 | -42.1% | 0.00% | 0.0% |
| Q2 2016 | $4,799,000 | – | 242,978 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |